Erythema multiforme major induced by sunitinib for metastatic renal cell carcinoma

Erythema multiforme major induced by sunitinib for metastatic renal cell carcinoma

There are currently several options for tyrosine kinase inhibitor as a systemic therapy for metastatic renal cell carcinoma (mRCC). The successful control of adverse events caused by such drugs, along with eliciting long-term maximum effect, are the major issues with respect to the treatment strateg...

Full description

Bibliographic Details
Main Authors: Daisuke Watanabe, Akemi Yamashita, Tadaaki Minowa, Kunihisa Miura, Akio Mizushima
Format: Article
Language:English
Published: Elsevier 2019-09-01
Series:Urology Case Reports
Online Access:http://www.sciencedirect.com/science/article/pii/S2214442019301974
id doaj-d41083ea6b8145dea20a0b406b66f541
record_format Article
spelling doaj-d41083ea6b8145dea20a0b406b66f5412020-11-24T20:43:51ZengElsevierUrology Case Reports2214-44202019-09-0126Erythema multiforme major induced by sunitinib for metastatic renal cell carcinomaDaisuke Watanabe0Akemi Yamashita1Tadaaki Minowa2Kunihisa Miura3Akio Mizushima4Department of Palliative Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan; Department of Urology, Koto Hospital, Tokyo, Japan; Corresponding author. Department of Palliative Medicine, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.Department of Urology, Koto Hospital, Tokyo, JapanDepartment of Urology, Koto Hospital, Tokyo, JapanDepartment of Anesthesiology and Pain Medicine, Koto Hospital, Tokyo, JapanDepartment of Palliative Medicine, Juntendo University Graduate School of Medicine, Tokyo, JapanThere are currently several options for tyrosine kinase inhibitor as a systemic therapy for metastatic renal cell carcinoma (mRCC). The successful control of adverse events caused by such drugs, along with eliciting long-term maximum effect, are the major issues with respect to the treatment strategy for mRCC. We herein report the clinical course of mRCC, in which erythema multiforme major was observed on the 13th day of the first course of sunitinib, but the symptoms improved after the immediate withdrawal of sunitinib, as well as the administration of topical steroids and oral antihistamines alone. Keywords: Erythema multiforme major, Renal cell carcinoma, Sunitinibhttp://www.sciencedirect.com/science/article/pii/S2214442019301974
collection DOAJ
language English
format Article
sources DOAJ
author Daisuke Watanabe
Akemi Yamashita
Tadaaki Minowa
Kunihisa Miura
Akio Mizushima
spellingShingle Daisuke Watanabe
Akemi Yamashita
Tadaaki Minowa
Kunihisa Miura
Akio Mizushima
Erythema multiforme major induced by sunitinib for metastatic renal cell carcinoma
Urology Case Reports
author_facet Daisuke Watanabe
Akemi Yamashita
Tadaaki Minowa
Kunihisa Miura
Akio Mizushima
author_sort Daisuke Watanabe
title Erythema multiforme major induced by sunitinib for metastatic renal cell carcinoma
title_short Erythema multiforme major induced by sunitinib for metastatic renal cell carcinoma
title_full Erythema multiforme major induced by sunitinib for metastatic renal cell carcinoma
title_fullStr Erythema multiforme major induced by sunitinib for metastatic renal cell carcinoma
title_full_unstemmed Erythema multiforme major induced by sunitinib for metastatic renal cell carcinoma
title_sort erythema multiforme major induced by sunitinib for metastatic renal cell carcinoma
publisher Elsevier
series Urology Case Reports
issn 2214-4420
publishDate 2019-09-01
description There are currently several options for tyrosine kinase inhibitor as a systemic therapy for metastatic renal cell carcinoma (mRCC). The successful control of adverse events caused by such drugs, along with eliciting long-term maximum effect, are the major issues with respect to the treatment strategy for mRCC. We herein report the clinical course of mRCC, in which erythema multiforme major was observed on the 13th day of the first course of sunitinib, but the symptoms improved after the immediate withdrawal of sunitinib, as well as the administration of topical steroids and oral antihistamines alone. Keywords: Erythema multiforme major, Renal cell carcinoma, Sunitinib
url http://www.sciencedirect.com/science/article/pii/S2214442019301974
work_keys_str_mv AT daisukewatanabe erythemamultiformemajorinducedbysunitinibformetastaticrenalcellcarcinoma
AT akemiyamashita erythemamultiformemajorinducedbysunitinibformetastaticrenalcellcarcinoma
AT tadaakiminowa erythemamultiformemajorinducedbysunitinibformetastaticrenalcellcarcinoma
AT kunihisamiura erythemamultiformemajorinducedbysunitinibformetastaticrenalcellcarcinoma
AT akiomizushima erythemamultiformemajorinducedbysunitinibformetastaticrenalcellcarcinoma
_version_ 1716818791102414848

Similar Items